During the 12-month follow-up period, increased FOXP3, IL-10, and TGF-β1 expression were observed leading to a conclusion that BM-MSC treatment has immunoregulatory effects on regulatory T cells of RA patients. Here, FOXP3 is linked to rheumatoid arthritis.